MGB Biopharma is dedicated to developing a new class of anti-infective medicines, particularly antibiotics based on Minor Groove Binder (MGBs) compounds. Their lead drug candidate, MGB-BP-3, has shown promising results in a Phase IIa clinical proof of concept study for the treatment of Clostridium difficile-associated diarrhea (CDAD).

MGB Biopharma’s focus is to further develop their completely new class of anti-infective medicine, starting with antibiotics based on Minor Groove Binder (MGBs) compounds.

The Company’s experienced management team have dedicated their initial focus to the development of a new class of small molecules, with specific antibacterial activity against susceptible and resistant bacteria. In providing a new class of drug to the field of antibacterial resistance, based on a truly novel mechanism of action, MGB Biopharma are unique, in that a truly new class and novel MoA was last seen in the year 2000.

There are many drugs used to treat bacterial infections, and generally they belong to classes which have been in use for several decades. Due to the rise in resistant strains of bacteria, several of these drugs are becoming less and less effective.

The Company’s progress has been rapid, and our lead drug candidate, MGB-BP-3, is currently in Phase I clinical safety studies, which will reach completion at the end of 2015. MGB-BP-3 is just the first in our new exciting class of anti-infectives.

MGB Biopharma commenced operations in 2010, and is funded by a syndicate of some of Scotland’s leading business angels, in co-operation with Scottish Enterprise.

Innovate UK

Archangels

Barwell Plc

Scottish Investment Bank

COM:MGB-BIOPHARMA

MGB Biopharma

Analysis Not Available